Award expands development resources following completion of $8 million convertible round fundraising in 2021

COLUMBUS, Ohio – August 31, 2021 Clarametyx Biosciences Inc. (“Clarametyx”), a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development, has awarded the company an additional $2.7 million in option funding to support critical development activities of the company’s lead candidate. CMTX-101 is a novel antibody therapy targeting the biofilm in development to treat moderate-to-severe pneumonia.

This milestone option extends the $2.4 million award received in November 2020 and is oriented toward progression of pre-IND activities, including dose selection, safety studies and manufacturing activities. Two additional options will be dependent on achievement of certain developmental milestones and that the product remains a competitive addition to the field, for a total award of up to $14.27 million.

“The continued support of CARB-X to advance our development programs into human trials is vital to demonstrating the potentially significant impact of our technology as a novel therapeutic option for serious biofilm-related bacterial infections,” said David Richards, Chief Executive Officer. “Combined with our fundraising efforts this year, we are well positioned to accelerate our efforts and expect to begin clinical studies in mid-2022.”

The company recently completed a private fundraising effort of $8 million in convertible notes to further fuel critical preclinical operational activities and accelerate research programs that will support rapid progression to the clinic.

Clarametyx’s technology continues to generate momentum and awareness as an important complementary approach to antibiotic strategies to effectively resolve challenging biofilm-related infections. The Company’s platform is designed to precisely remove a universal, pathogen-agnostic target within the biofilm matrix, rapidly and effectively collapsing the protective shield and rendering the bacteria vulnerable to immune and antibiotic attack.

This news release is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by awards from the Wellcome Trust and Germany’s Federal Ministry of Education and Research (BMBF). The contents are solely the responsibility of the author and do not necessarily represent the official views of CARB-X or CARB-X funders.

About CARB-X

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is led by Boston University and funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services, the Wellcome Trust, a global charity based in the UK working to improve health globally, Germany’s Federal Ministry of Education and Research (BMBF), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).  CARB-X is investing up to $480 million from 2016-2022 to support innovative antibiotics and other therapeutics, vaccines, and rapid diagnostics. CARB-X supports the world’s largest and most innovative pipeline of preclinical products against drug-resistant infections. CARB-X is headquartered at Boston University School of Law.  Follow us on Twitter @CARB_X.

About Clarametyx Biosciences

Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response or antibiotic intervention. The Columbus, Ohio-based company is building a dynamic pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms. Its lead candidate, CMTX-101, is a humanized monoclonal antibody in preclinical development for hospital-acquired pneumonia. For more information, visit us on the web or on LinkedIn.

 Media Contact:

Kellie Hotz

# # #